Expert Interview
Evaluating Phase II ABBV-RGX-314 Study Results for Wet AMD from REGENXBIO (RGNX)
Ticker(s): RGNXAn ophthalmologist specializing in retinal diseases, particularly age-related macular degeneration, with experience in gene therapy and clinical trials focused on reducing injection frequency in chronic eye diseases.
With a 97% reduction in anti-VEGF injection frequency at nine months, how impactful could this be for wet AMD patients struggling with frequent injections?
Added By: catalin_adminABBV-RGX-314’s data suggests effectiveness in both eyes. How significant is this for patients with bilateral wet AMD, and what are the potential practical benefits?
Added By: catalin_adminThe study noted sustained best-corrected visual acuity and stable retinal thickness. Can you discuss the importance of these factors in assessing ABBV-RGX-314’s efficacy?
Added By: catalin_adminConsidering ABBV-RGX-314’s potential as a one-time treatment, what are the long-term implications for patient adherence and vision preservation?
Added By: catalin_adminWith no cases of intraocular inflammation or serious adverse events, how reassuring is this safety data for ABBV-RGX-314’s future use?
Added By: catalin_adminCurrent anti-VEGF treatments require regular injections. How does ABBV-RGX-314’s profile compare in addressing both efficacy and treatment burden?
Added By: catalin_adminGiven the high frequency of injections needed in standard care, how might ABBV-RGX-314’s reduced burden improve real-world outcomes for wet AMD patients?
Added By: catalin_adminAs gene therapy for retinal diseases advances, what do you foresee as the next steps in evaluating ABBV-RGX-314 for broader clinical use?
Added By: catalin_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
